Leflunomide as a novel treatment option in severe atopic dermatitis

British Journal of Dermatology

Volumn 150, Issue 6, 2004, Pages 1182-1185

  Schmitt, J ^a   Wozel, G ^a   Pfeiffer, C ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adult patient; Adverse drug reactions; Immunosuppression; Leflunomide; Long term treatment; Severe atopic dermatitis

Indexed keywords

CORTICOSTEROID; LEFLUNOMIDE; MOMETASONE FUROATE; PREDNICARBATE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHRODERMA; HUMAN; LABORATORY TEST; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE;

ACUTE DISEASE; ADULT; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 3142658634     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2003.05846.x     Document Type: Article

References (15)

1. Verboom P, Hakkaart-Van Roijen L, Sturkenboom M et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147: 716-24.
2. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25: 3-7.
3. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8.
4. Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147: 324-30.
5. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2001; 27: 3-7.
6. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13-14.
7. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
8. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11-18.
9. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003: 361: 151-60.
10. Rückemann K, Fairbanks L, Carrey BA et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen stimulated lymphocytes from healthy humans. J Biol Chem 1998; 34: 21682-91.
11. Wozel G, Pfeiffer C. Leflunomid - ein neues Medikament zur pharmakologischen Immunmodulation. Hautarzt 2002; 53: 309-15.
12. Dimitijevic M, Bartlett R. Leflunomide, a novel immunomodularing drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatic arthritis. Inflamm Res 1996; 45: 550-6.
13. Kehrer T, Blümlein K, Wozel G. Eotaxin release is suppressed by the metabolite A 77 1726 of the novel immunomodulating agent leflunomide. Eur J Allergy Clin Immunol 2001; 56 (S68): 144.
14. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide. Arch Dermatol 2000; 136: 1204-5.
15. Reich K, Hummel KM, Beckmann I et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002; 146: 335-6.